Immunovant Analyst Ratings
BenzingaMar 28 06:48 ET
Immunovant Analyst Ratings
BenzingaMar 25 12:10 ET
Buy Rating for Immunovant Amidst Strong Market Position and Promising Batoclimab Trials
TipRanksMar 21 13:15 ET
Immunovant Analyst Ratings
BenzingaMar 13 08:36 ET
Immunovant Analyst Ratings
BenzingaFeb 20 06:30 ET
Immunovant Analyst Ratings
BenzingaFeb 15 06:38 ET
Buy Rating Affirmed on Immunovant's Promising Pipeline and Strategic Clinical Advancements
TipRanksFeb 15 01:16 ET
Analysts Are Bullish on Top Healthcare Stocks: Immunovant (IMVT), 4D Molecular Therapeutics (FDMT)
TipRanksFeb 13 06:20 ET
Buy Rating Affirmed on Immunovant Amidst Strategic Growth and Pipeline Strength
TipRanksFeb 13 05:03 ET
Immunovant (IMVT) Poised for Growth: A Buy Rating Backed by Strong Pipeline and Upcoming Catalysts
TipRanksFeb 13 04:59 ET
Immunovant's Buy Rating: Market Opportunities and Positive Trial Outcomes for Batoclimab
TipRanksFeb 5 15:55 ET
Stifel Nicolaus Keeps Their Buy Rating on Immunovant (IMVT)
TipRanksDec 25, 2023 21:05 ET
Analysts' Top Healthcare Picks: Hookipa Pharma (HOOK), Immunovant (IMVT)
TipRanksDec 25, 2023 00:40 ET
Stifel Nicolaus Sticks to Their Buy Rating for Immunovant (IMVT)
TipRanksDec 21, 2023 07:26 ET
Immunovant's Strong Phase 2 Results and Positive Outlook Prompt Buy Rating
TipRanksDec 21, 2023 06:56 ET
HC Wainwright & Co. Maintains Buy on Immunovant, Raises Price Target to $51
BenzingaDec 21, 2023 06:09 ET
Immunovant Analyst Ratings
BenzingaDec 21, 2023 06:09 ET
Analysts Conflicted on These Healthcare Names: Halozyme (HALO), Immunovant (IMVT) and Henry Schein (HSIC)
TipRanksDec 21, 2023 06:00 ET
Buy Rating Affirmed: Immunovant's Promising Clinical Data and Market Potential for Graves' Disease Treatment
TipRanksDec 21, 2023 05:57 ET
Deutsche Bank Initiates Coverage On Immunovant With Buy Rating, Announces Price Target of $50
BenzingaDec 12, 2023 05:11 ET
No Data
No Data